Kinase News and Research

RSS

PLX4032 trial shows high degree of selectivity to achieve tumor shrinkage

Plexxikon today announced publication of key data in this week's edition of Nature demonstrating that the high degree of selectivity of PLX4032 (RG7204) enables substantial RAF/MEK/ERK pathway inhibition, which may be necessary to achieve significant tumor shrinkage and clinical response in patients with BRAF mutant melanoma.

8 Sep 2010

Quick increase of calcium concentration in cells rapidly trigger Aurora-A kinase enzyme activity

Aurora-A kinase (AurA) is an enzyme that is hyperactive in many cancers and drives tumor cell proliferation. Several AurA inhibitors are currently being tested in clinical trials to see if they slow tumor growth. Now, researchers in the Developmental Therapeutics Program at Fox Chase Cancer Center have identified an activation signal for AurA. They report in the September 7 issue of Nature Communications that a quick increase in the calcium concentration in a cell rapidly triggers AurA kinase activity.

8 Sep 2010

Researchers develop new RNA molecule approach to kill cancer cells

Researchers at the California Institute of Technology (Caltech) have engineered a fundamentally new approach to killing cancer cells. The process developed by Niles Pierce, associate professor of applied and computational mathematics and bioengineering at Caltech, and his colleagues uses small RNA molecules that can be programmed to attack only specific cancer cells then, by changing shape, those molecules cause the cancer cells to self destruct.

8 Sep 2010

CytRx commences PROACT Phase 2 clinical trial of bafetinib for advanced prostate cancer

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced initiation of the PROstate Advanced Cancer Treatment (PROACT) Phase 2 proof-of-concept clinical trial to evaluate the efficacy and safety of bafetinib in patients with advanced prostate cancer.

7 Sep 2010

Study shows molecular imaging benefits treatment planning for wide spectrum of cancers

A series of studies published in the September Journal of Nuclear Medicine (JNM) show that molecular imaging plays a critical role in the evaluation and treatment planning for a broad spectrum of cancers, including thyroid cancer and lymphoma.

3 Sep 2010

Diabetes drug metformin exhibits potential against tobacco-induced lung tumors

Metformin, a drug commonly used to treat type 2 diabetes, shows potential in the prevention of tobacco-induced lung tumors, according to early research conducted at the National Cancer Institute (NCI).

3 Sep 2010

Gene mutations that express LRRK2 linked to increased risk of Parkinson's disease: Researchers

A significant number of Parkinson's disease patients have a mutation of the enzyme Leucine-Rich Repeat Protein Kinase 2 (LRRK2, also known as dardarin). However, little is understood about how it is regulated or functions. In a new paper in the Signal Knowledge Environment of the Biochemical Journal, Dario Alessi and colleagues from the University of Dundee demonstrate that a family of proteins, the 14-3-3 proteins, interact with LRRK2.

2 Sep 2010

TGen researchers use RNAi-based screening to study Ewing's sarcoma

The first study of Ewing's sarcoma that screened hundreds of genes based on how they affect cell growth has identified two potential anti-cancer drug targets, according to a scientific paper by the Translational Genomics Research Institute published this month in the journal Molecular Cancer.

2 Sep 2010

Afferent Pharmaceuticals' P2X3 receptor antagonist reduces bladder hyperactivity

Afferent Pharmaceuticals, a clinical-stage biopharmaceutical company developing first-in-class, small molecule compounds that target P2X3 receptors, today announced preclinical in vivo results demonstrating that an investigational P2X3 receptor antagonist reduced experimentally induced bladder hyperactivity.

26 Aug 2010

Study identifies four genetic variants associated with ESRD disease in Chinese diabetic patients

Examination of a gene involved in cell signaling finds that four common variants of this gene are associated with the development of end-stage renal disease in Chinese patients with type 2 diabetes, according to a study in the August 25 issue of JAMA.

25 Aug 2010

Research on OGF-OGFr complex helps to understand pathobiology of diseases

Researchers at The Pennsylvania State University College of Medicine, Hershey, Pennsylvania have discovered that the Opioid Growth Factor (OGF, [Met5]-enkephalin) and its receptor, OGFr, a clinically important system with potent antitumor properties, has controlled entry from the cytoplasm to the nucleus. The nucleocytoplasmic passage of OGF-OGFr is critical to cell proliferation and suggests that there are hierarchical levels of nuclear import.

24 Aug 2010

Researchers find new drug to treat circadian rhythm disorders

Researchers funded by the Biotechnology and Biological Sciences Research Council (BBSRC) and the Medical Research Council (MRC) have successfully used a drug to reset and restart the natural 24 hour body clock of mice in the lab. The ability to do this in a mammal opens up the possibility of dealing with a range of human difficulties including some psychiatric disorders, jet lag and the health impacts of shift work.

24 Aug 2010

Pfizer reports Progression-Free survival in SUN 1087 combination trial of sunitinib with erlotinib for NSCLC

Pfizer Inc. announced today that the SUN 1087 trial of sunitinib in combination with erlotinib versus erlotinib demonstrated a statistically significant improvement in Progression-Free but not in Overall Survival in patients with previously treated advanced non-small cell lung cancer (NSCLC).

24 Aug 2010

Study supports role for SNARK protein in regulating glucose transport during muscle contraction and exercise

Skeletal muscles combust both lipids and carbohydrates during exercise. The carbohydrates consist of both glycogen stored in the muscles as well as glucose extracted from the blood. Being a major sink for glucose disposal, skeletal muscle represents an important model tissue for studying the intracellular signaling pathways leading to increased glucose transport.

21 Aug 2010

Immunosuppressive therapy benefits necrotizing myopathy patients with novel autoantibody specificity

Researchers at Johns Hopkins University School of Medicine have identified a subgroup of patients with necrotizing myopathy who have a novel autoantibody specificity that makes them potential candidates for immunosuppressive therapy. The complete study is published in the September issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology.

20 Aug 2010

Study shows increase in IL-6 secretion can reduce Tarceva sensitivity to treat lung tumor cells

One of the most tantalizing developments in anti-cancer therapy over recent years has been the advent of targeted treatments, which have proven highly effective in holding aggressive cancers at bay in certain patients, although typically only for a limited period of time.

18 Aug 2010

SIK2 impacts cell division cycle, regulates ovarian cancer response to chemotherapy: Research

For the first time, Salt Inducible Kinase 2 (SIK2) has been found to play a critical role in cell division and to regulate the response of some ovarian cancers to chemotherapy.Findings were reported by researchers from The University of Texas MD Anderson Cancer Center in the August issue of Cancer Cell. The study adds to growing evidence that combination therapies targeting different phases of the cell division cycle are vital for optimal cancer treatment.

17 Aug 2010

Researchers find link between chronic inflammation and cancer

Virginia Commonwealth University Massey Cancer Center researchers have uncovered a new link between chronic inflammation and cancer. Although cancers do not always cause inflammation, chronic inflammation is known to help tumor cells grow.

17 Aug 2010

Astex and MMRC commence Phase II clinical trial of AT7519 CDK inhibitor in multiple myeloma

Astex Therapeutics, the UK-based biotechnology company developing targeted therapies for oncology and virology, and the Multiple Myeloma Research Consortium announced today the initiation of a Phase II clinical trial of the cyclin-dependent kinase inhibitor, AT7519, to treat patients with relapsed or refractory multiple myeloma, an incurable blood cancer. The trial is designed to investigate both single agent and combination activity of AT7519 with bortezomib (Velcade®).

13 Aug 2010

AVEO achieves enrollment target for tivozanib global Phase 3 clinical trial in advanced renal cell carcinoma

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it has achieved its enrollment target for TIVO-1, its global Phase 3 clinical trial for its oral, triple VEGF receptor inhibitor, tivozanib, in patients with advanced renal cell carcinoma. In February of this year, AVEO initiated enrollment in TIVO-1, and has successfully reached the target enrollment of 500 patients.

12 Aug 2010

Kinase News and Research

PLX4032 trial shows high degree of selectivity to achieve tumor shrinkage

Quick increase of calcium concentration in cells rapidly trigger Aurora-A kinase enzyme activity

Researchers develop new RNA molecule approach to kill cancer cells

CytRx commences PROACT Phase 2 clinical trial of bafetinib for advanced prostate cancer

Study shows molecular imaging benefits treatment planning for wide spectrum of cancers

Diabetes drug metformin exhibits potential against tobacco-induced lung tumors

Gene mutations that express LRRK2 linked to increased risk of Parkinson's disease: Researchers

TGen researchers use RNAi-based screening to study Ewing's sarcoma

Afferent Pharmaceuticals' P2X3 receptor antagonist reduces bladder hyperactivity

Study identifies four genetic variants associated with ESRD disease in Chinese diabetic patients

Research on OGF-OGFr complex helps to understand pathobiology of diseases

Researchers find new drug to treat circadian rhythm disorders

Pfizer reports Progression-Free survival in SUN 1087 combination trial of sunitinib with erlotinib for NSCLC

Study supports role for SNARK protein in regulating glucose transport during muscle contraction and exercise

Immunosuppressive therapy benefits necrotizing myopathy patients with novel autoantibody specificity

Study shows increase in IL-6 secretion can reduce Tarceva sensitivity to treat lung tumor cells

SIK2 impacts cell division cycle, regulates ovarian cancer response to chemotherapy: Research

Researchers find link between chronic inflammation and cancer

Astex and MMRC commence Phase II clinical trial of AT7519 CDK inhibitor in multiple myeloma

AVEO achieves enrollment target for tivozanib global Phase 3 clinical trial in advanced renal cell carcinoma

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News